Analysis of CRBSI Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter
Analysis of CRBSI (Catheter-Related Blood Stream Infection) Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Detailní popis
This is a U.S. multi - centre, prospective, non-randomized post approval registry. Approximately one hundred and twenty patients will be implanted with a NexSite HD catheter at four to eight U.S. sites where hemodialysis catheters are routinely implanted. Each site may enrol a maximum of 50 patients. Enrolled patients will be followed from device placement to device removal or 180 days post device placement. Patients will be enrolled once only.
The primary endpoint is CRBSI rate related to the NexSite HD catheter. Determination of infection will be decided by the investigator and if necessary adjudicated by the CEC (Clinical Events Committee) based on blood culture results, regardless of whether the catheter is removed.
Secondary endpoints for the study are
- Successful placement and continued use of the NexSite HD device designed for use in patients requiring long term hemodialysis.
- Healing of catheter exit site
- Tunnel Infections
- Exit site infections
- Early non-infectious complications associated with CVCs
- Late non-infectious complications associated with Central Venous Catheters
Typ studie
Typ studie
Zápis (Aktuální)
Zápis
Fáze
Fáze
- Nelze použít
Kontakty a umístění
Studijní místa
-
-
North Carolina
-
Greenville, North Carolina, Spojené státy, 27834
- Eastern Nephrology Associates
-
New Bern, North Carolina, Spojené státy, 28542
- Eastern Nephology Associates
-
Raleigh, North Carolina, Spojené státy, 27610
- Capital Nephrology Associates
-
-
South Carolina
-
Orangeburg, South Carolina, Spojené státy, 29118
- South Carolina Nephrology and Hypertension Center Inc
-
-
Texas
-
Lubbock, Texas, Spojené státy, 79416
- Lubbock Vascular Access Centre
-
San Antonio, Texas, Spojené státy, 78215
- Renal Associates
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- The patient shall be 18 - 80 years old.
- The patient requires the placement of a long term tunnelled HD catheter for administration of hemodialysis.
- The patient has anticipated survival in excess of 90 days from the anticipated date of catheter placement.
- The patient has the ability to understand the research subject information and sign a written Informed Consent form which must be obtained prior to initiation of the study.
- The patient receives the catheter via the internal jugular or subclavian vein.
- All female patients of child bearing potential must complete a negative pregnancy test and will confirm that they are not breastfeeding.
Exclusion Criteria:
- The patient is participating in another IRB (Institutional Review Board) clinical trial, which modifies standard-of-care treatment and/or involves an investigational device or drug.
- The patient has a confirmed or suspected infection, bacteraemia or septicaemia.
- The patient's physiology is NOT suitable for placement of the NexSite device; this will include an examination of the anatomy at the proposed catheter exit site.
- The patient is known or suspected to have allergies to the materials used in the construction of the device.
- The patient has previously suffered from coagulation issues or has had vascular surgery at the proposed placement site.
- The patient has received radiation treatment at the proposed catheter placement site.
- The patient has severe chronic obstructive lung disease.
- The patient is pyretic within 72 hours (temperature ≥38o C or 100.4oF) prior to placement and/or has received antimicrobial drugs within two weeks prior to catheterisation.
- The patient is female of child bearing potential not using adequate contraception. (Adequate contraception is defined as abstinence, intrauterine device [IUD], birth control pills, or spermicidal gel with diaphragm or condom)
- The patient has another indwelling catheter.
- The patient has non-healing diabetic foot ulcers.
- The patient did not give informed consent.
- The patient would be unavailable for follow-up.
- The patient is a permanent nursing home resident.
- The proposed access site is not the internal jugular or subclavian vein.
- The patient is scheduled to undergo an elective surgical procedure (other than a procedure to create a graft or fistula) within the study timeframe.
- Any other condition that the Investigator believes should exclude the patient from the study.
- The patient does not have English or Spanish as their first language.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Jiný
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: NexSite HD Patients
NexSite HD patient catheter device placement
|
Measurement of CRBSI rate and other device related adverse events in patients with NexSite HD Catheter.
|
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Number of participants with Catheter-Related Blood Stream Infection (CRBSI)(bacteremia/fungemia) as an adverse event.
Časové okno: Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
|
Number of participants with a confirmed CRBSI for the duration of catheter use or to 180 days post device placement (whichever occurs first)
|
Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Number of participants with adverse events associated with device placement and use.
Časové okno: Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
|
Number of participants with adverse events associated with device placement and for the duration of catheter use or to 180 days post device placement.
|
Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
|
|
Number of participants with unhealed catheter exit sites
Časové okno: Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
|
Number of participants with unhealed exit sites for the duration of catheter use or to 180 days post device placement (whichever occurs first)
|
Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
|
|
Number of participants with tunnel infection as an adverse event
Časové okno: Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
|
Number of participants with a tunnel infection for the duration of catheter use or to 180 days post device placement (whichever occurs first)
|
Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
|
|
Number of participants with exit site infection as an adverse event
Časové okno: Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
|
Number of participants with a exit site infection for the duration of catheter use or to 180 days post device placement (whichever occurs first)
|
Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
|
|
Number of participants with Pneumothorax, haemothorax, arrhythmia, air embolism or arterial perforation as an adverse event.
Časové okno: 1 day of device placement
|
Number of participants with non-infectious catheter complications within one day of placement.
|
1 day of device placement
|
|
Number of participants with Catheter dislodgement, Catheter tip dislodgement and catheter thrombosis as an adverse event.
Časové okno: Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
|
Number of participants with late non infectious complications for the duration of catheter use or to 180 days post device placement (whichever occurs first).
|
Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Vyšetřovatelé
Vyšetřovatelé
- Vrchní vyšetřovatel: Jeffrey G Hoggard, MD, Capital Nephrology Associates
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Aktuální)
Primární dokončení
Dokončení studie (Aktuální)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
Další identifikační čísla studie
- TR 0147
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Konečné stadium onemocnění ledvin
-
NCT03358030DokončenoEnd-stage Renal Disease (ESRD)
-
NCT01228279DokončenoEnd-stage Renal Disease (ESRD) | Nemoc ledvin
-
NCT02553889DokončenoEnd-stage Renal Disease (ESRD)
-
NCT00548249Dokončeno
-
NCT01222234DokončenoEnd-stage Renal Disease (ESRD) | Chronické onemocnění ledvin (CKD)
-
NCT07303179Aktivní, ne náborEnd-stage Renal Disease (ESRD) | Údržbová hemodialýza (MHD)
-
NCT07464418DokončenoHemodialýza | Chronické onemocnění ledvin | End-stage Renal Disease (ESRD)
-
NCT07370441Zápis na pozvánkuNutriční stav | Renální substituční terapie | End-stage Renal Disease (ESRD) | Peritoneální dialýza (PD)
-
NCT07249229DokončenoHemodialýza | End-stage Renal Disease (ESRD)
Klinické studie na NexSite HD Patients
-
NCT07489131Nábor
-
NCT04932148Nábor
-
NCT04577768Dokončeno
-
NCT06409143Nábor
-
NCT02098798DokončenoZánětlivé onemocnění střev
-
NCT03602716Ukončeno
-
NCT07184697Aktivní, ne nábor
-
NCT06647550Nábor